Douglas Carr
Director of Finance/CFO at CENTURY THERAPEUTICS, INC.
Net worth: 1 M $ as of 30/03/2024
Profile
Douglas Carr's career history includes current and former positions as well as his education history.
Currently, he is the Senior Vice President-Finance & Operations at Century Therapeutics, Inc. Prior to his current role, he held the position of Vice President-Finance & Operations at Century Therapeutics, Inc. Previously, he worked as a Business Director-Franchise Division at Zocor Ltd., a Controller-Pediatric Vaccines Franchise at Merck & Co., Inc., and a Financial Controller at Omthera Pharmaceuticals, Inc. Mr. Carr obtained his undergraduate degree from Rutgers State University of New Jersey.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
06/03/2024 | 317,580 ( 0.39% ) | 1 M $ | 30/03/2024 |
Douglas Carr active positions
Companies | Position | Start |
---|---|---|
CENTURY THERAPEUTICS, INC. | Director of Finance/CFO | 01/02/2024 |
Former positions of Douglas Carr
Companies | Position | End |
---|---|---|
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Director of Finance/CFO | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Zocor Ltd. | Corporate Officer/Principal | - |
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Comptroller/Controller/Auditor | - |
Training of Douglas Carr
Rutgers State University of New Jersey | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
CENTURY THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Omthera Pharmaceuticals, Inc.
Omthera Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ. | Health Technology |
Zocor Ltd. | |
Century Therapeutics, Inc. /Old/
Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
- Stock Market
- Insiders
- Douglas Carr